With approval of first trastuzumab biosimilar, WHO moves step closer to cheaper breast cancer treatment

The cheaper but equally effective biotherapeutic medicines are produced from biological sources such as cells rather than synthesised chemicals.

They are usually manufactured by companies after the patent on the original product has expired.

"WHO prequalification of biosimilar trastuzumab is good news for women everywhere," said WHO director general Dr Tedros Adhanom Ghebreyesus.

"Women in many cultures suffer from gender disparity when it comes to accessing health services. In poor countries, there is the added burden of a lack of access to treatment for many, and the high cost of medicines. "Effective, affordable breast cancer treatment should be a right for all women, not the privilege of a few, " he added.

A few biosimilars of trastuzumab have come on the market in recent years, but none had previously been prequalified by WHO.

WHO prequalification gives countries the assurance that they are purchasing "quality health products".

Read Also: IIT-G collaborates with IISc, Bangalore for breast cancer research

"We need to act now and try to avoid more preventable deaths," said Dr Mariangela Simao, WHO assistant director general for Medicines and Health Products.

"The availability of biosimilars has decreased prices, making even innovative treatments more affordable and hopefully available to more people."

Read Also: PV Sindhu, Ushalakshmi Breast Cancer Foundation raise awareness for breast cancer